-- 中国国家药品监督管理总局批准了优凯制药（上海证券交易所代码：688658）旗下子公司北京跃康科创药业科技有限公司和杭州天龙药业股份有限公司的YKYY025注射剂的I期临床试验申请。 根据周二提交给上海证券交易所的公告，该疫苗适用于预防由呼吸道合胞病毒引起的下呼吸道疾病。 另据一份文件显示，监管机构还批准了这两家子公司研发的用于治疗带状疱疹的YKYY026疫苗。
Related Articles
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF
Asia
Sprintex Raising AU$1.1 Million Via Convertible Notes Issue
Sprintex (ASX:SIX) is raising about AU$1.1 million through the issue of nearly 1.1 million convertible notes at a price of AU$1 each, according to a Monday filing with the Australian bourse.The notes will mature on June 30, 2027, and bear interest at 8% per year, per the filing.Holders of the notes can convert them into Sprintex ordinary shares at any time after June 30 and before their maturity.The company said it plans to use the funds for general working capital purposes, to expand its sales team, and to fulfill customer orders.
$ASX:SIX
Asia
Immutep Says Bank of New York Mellon Increases Stake
Immutep (ASX:IMM) received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 21.11% from 20.08%, according to a Monday filing with the Australian bourse.Bank of New York Mellon and its affiliates now owns over 311 million shares in the company, the filing said.
$ASX:IMM